This Year's Highlights

• Presented data from first mRCC trial in November 2005 at AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics.
• Started new mRCC trial with new process in May 2006.
• Started trials in CLL and HIV with new process in July 2006.

Anticipated Highlights

• Data from mRCC trial in 2007.
• Data from CLL trial in 2007.
• Data from HIV trial in 2007.

Corporate Mission

Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient?s disease. This new generation of personalized cancer and HIV therapeutics trains the immune system to recognize and attack the disease. Argos? scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases.

Argos is a private biotechnology company headquartered in Research Triangle Park, NC.  The company has multiple clinical trial programs in renal cell carcinoma (RCC), chronic lymphocytic leukemia (CLL) and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the pharmaceutical division of Kirin Brewery Company, Limited.